Preview

Вопросы современной педиатрии

Расширенный поиск

Применение блокаторов фактора некроза опухоли в терапии ревматоидного артрита. Комментарии к результатам метаанализа рандомизированных испытаний N. Graudal и соавт.: окончательные выводы или почва для размышлений?

https://doi.org/10.15690/vsp.v15i3.1571

Полный текст:

Аннотация

.

Об авторе

М. М. Костик
Санкт-Петербургский государственный педиатрический медицинский университет, Санкт-Петербург, Российская Федерация
Россия

кандидат медицинских наук, доцент кафедры госпитальной педиатрии Санкт-Петербургского государственного педиатрического медицинского университета Адрес: 194100, Санкт-Петербург, ул. Литовская, д. 2, тел.: +7 (812) 416-52-98



Список литературы

1. Dickersin K, Berlin JA. Meta-analysis: State-of-the-science. Epide miol Rev. 1992;14(1):154–176.

2. Glass GV. Primary, secondary, and meta-analysis of research. Educ Res. 1976;5(10):3–8. doi: 10.3102/0013189x005010003.

3. Egger M, Smith GD. Meta-Analysis: Potentials and promise. BMJ. 1997;315(7119):1371–1374. doi: 10.1136/bmj.315.7119.1371.

4. van Vollenhoven RF, Ernestam S, Geborek P, et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. Lancet. 2009;374(9688):459–466. doi: 10.1016/s0140-6736(09)60944-2.

5. Kavanaugh A, Fleischmann RM, Emery P, et al. Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study. Ann Rheum Dis. 2013;72(1):64–71. doi: 10.1136/annrheumdis-2011-201247.

6. Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004;363(9410): 675–681. doi: 10.1016/s0140-6736(04)15640-7.

7. Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73(3):492–509. doi: 10.1136/ annrheumdis-2013-204573.

8. Brunner HI, Ruperto N, Zuber Z, et al. Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. Ann Rheum Dis. 2015;74(6):1110–1117. doi: 10.1136/annrheumdis-2014-205351.

9. Lovell DJ, Ruperto N, Goodman S, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008;359(8):810–820. doi: 10.1056/nejmoa0706290.

10. Ravelli A, Moretti C, Temporini F, et al. Combination therapy with methotrexate and cyclosporine A in juvenile idiopathic arthritis. Clin Exp Rheumatol. 2002;20(4):569–572.

11. Костик М.М., Чикова И.А., Исупова Е.А., и др. Применение тоцилизумаба у детей с полиартикулярным вариантом ювенильного идиопатического артрита, резистентного к терапии метотрексатом // Фарматека. — 2015.— №1(294) — С. 66–75. [Kostik MM, Chikova IA, Isupova EA, et al. Primenenie totsilizumaba u detei s poliartiku lyarnym variantom yuvenil’nogo idiopaticheskogo artrita, rezistentnykh k terapii metotreksatom. Farmateka. 2015;(1(294)):66–75. (In Russ).]

12. Kostik MM, Dubko M, Isupova E, et al. Achievement remission in different juvenile idiopathic arthritis categories during adalimumab therapy: data of retrospective analysis. Ann Rheum Dis [Internet]. 2016 [cited 2016 Mar 17];75(Suppl 2):1201. doi: 10.1136/annrheumdis- 2016-eular.5654. Available from: http://www.abstracts2view.com/ eular/view.php?nu=EULAR16L_AB0876&terms=.

13. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheumatol. 2005; 52(11):3381– 3390. doi: 10.1002/art.21405.

14. Moreland LW, O’Dell JR, Paulus HE, et al. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of early aggressive rheumatoid arthritis trial. Arthritis Rheumatol. 2012;64(9):2824–2835. doi: 10.1002/ art.34498.

15. Bae SC, Gun SC, Mok CC, et al. Improved health outcomes with etanercept versus usual DMARD therapy in an Asian population with established rheumatoid arthritis. BMC Musculoskelet Disord. 2013;14(1):13. doi: 10.1186/1471-2474-14-13.

16. Van Vollenhoven RF, Geborek P, Forslind K, et al. Conventional combination treatment versus biological treatment in methotrexate refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial. Lancet. 2012;379(9827):1712–1720. doi: 10.1016/s0140-6736(12) 60027-0.

17. Kim HY, Hsu PN, Barba M, et al. Randomized comparison of etanercept with usual therapy in an Asian population with active rheumatoid arthritis: the APPEAL trial. Int J Rheum Dis. 2012; 15(2):188–196. doi: 10.1111/j.1756-185x.2011.01680.x.

18. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med. 2007;146(6):406–415. doi:10.7326/0003-4819-146-6-200703200-00005.

19. O’Dell JR, Mikuls TR, Taylor TH, et al. Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med. 2013;369(4):307–318. doi: 10.1056/nejmoa1303006.

20. Nam JL, Villeneuve E, Hensor EM, et al. Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study). Ann Rheum Dis. 2014;73(1):75–85. doi: 10.1136/ annrheumdis-2013-203440.

21. Стародубов В.И., Улумбекова Г.Э. Здравоохранение России: сценарии развития // ОРГЗДРАВ: новости, мнения, обучение. — 2015. — №2(2) — С. 34–47. [Starodubov VI, Ulumbekova GE.Healthcare in Russia: development scenarios. ORGZDRAV: novosti, mneniya, obuchenie. 2015;(2(2)):34–47. (In Russ).]

22. Hopkins AM, Proudman SM, Vitry AI, et al. Ten years of publicly funded biological disease-modifying antirheumatic drugs in Australia. Med J Aust. 2016;204(2):64–68. doi: 10.5694/mja15.00716.

23. Barnabe C, Thanh NX, Ohinmaa A, et al. Effect of remission definition on healthcare cost savings estimates for patients with rheumatoid arthritis treated with biologic therapies. J Rheumatol. 2014;41(8):1600–1606. doi: 10.3899/jrheum.131449.

24. Doan QV, Chiou CF, Dubois RW. Review of eight pharmacoeconomic studies of the value of biologic DMARDs (adalimumab, etanercept, and infliximab) in the management of rheumatoid arthritis. J Manag Care Pharm. 2006;12(7):555–569. doi: 10.18553/jmcp.2006.12.7.555.


Для цитирования:


Костик М.М. Применение блокаторов фактора некроза опухоли в терапии ревматоидного артрита. Комментарии к результатам метаанализа рандомизированных испытаний N. Graudal и соавт.: окончательные выводы или почва для размышлений? Вопросы современной педиатрии. 2016;15(3):315-317. https://doi.org/10.15690/vsp.v15i3.1571

For citation:


Kostik M.M. Administration of TNF- Inhibitors for Rheumatoid Arthritis Therapy. Comments to the Results of a Meta-Analysis of Randomized Trials by N. Graudal et al.: Final or Thought Provoking Conclusions? Current Pediatrics. 2016;15(3):315-317. (In Russ.) https://doi.org/10.15690/vsp.v15i3.1571

Просмотров: 233


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1682-5527 (Print)
ISSN 1682-5535 (Online)